MRD in multiple myeloma: Utility of MRI

The increasing percentage of patients achieving deep responses in multiple myeloma (MM) has led to the need for more sophisticated instruments to measure residual disease as a potential source of relapse. Since minimal residual disease (MRD) assessment is mostly performed on a bone marrow specimen from a certain area of the body, such samples have the limitation that they might not really represent the actual tumor burden, because focal accumulations of malignant cells might be either hit or missed.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research